Pharvaris announces accepted presentations at the EAACI Annual Congress 2026 on their bradykinin B2 receptor antagonist, deucrictibant.
Quiver AI Summary
Pharvaris, a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases like hereditary angioedema (HAE), announced its participation in the EAACI Annual Congress 2026. The company will present one oral abstract and seven additional abstracts, including flash talks and poster presentations, from June 12-15, 2026, in Istanbul, Turkey. Key presentations will include findings from the Phase 3 RAPIDe-3 trial on deucrictibant for on-demand HAE treatment and ongoing studies related to its safety and efficacy. Pharvaris aims to establish a new standard of care for bradykinin-mediated angioedema with treatments that combine convenience and efficacy.
Potential Positives
- Acceptance of multiple abstracts for presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress enhances the company's visibility and credibility in the biopharmaceutical field.
- Presentation of Phase 3 trial results for Oral Deucrictibant demonstrates the company's commitment to advancing treatment options for hereditary angioedema, addressing significant unmet medical needs.
- Pharvaris is preparing marketing authorization applications for its oral bradykinin B2 receptor antagonists, indicating progress towards bringing novel therapies to market.
- The ongoing global pivotal Phase 3 study of deucrictibant extended-release tablet is a positive sign of the company’s continued research and development efforts in treating bradykinin-mediated angioedema.
Potential Negatives
- The company has not disclosed any results from the Phase 3 RAPIDe-3 trial in the press release, which may raise concerns regarding the effectiveness and safety of its lead product, deucrictibant.
- The reliance on multiple presentations at an upcoming congress for communication of their findings may be perceived as a lack of sufficient engagement with immediate investors and stakeholders.
- There is no mention of any potential market competition for deucrictibant or how it plans to differentiate itself from existing treatments, which could leave questions about its market viability.
FAQ
What is Pharvaris presenting at the EAACI Annual Congress 2026?
Pharvaris will present one oral abstract and seven flash talk/poster presentations related to bradykinin-mediated diseases.
When and where is the EAACI Annual Congress 2026?
The conference will take place from June 12-15, 2026, in Istanbul, Turkey.
Who will present at the EAACI Annual Congress?
Notable presenters include Mauro Cancian, M.D., Ph.D., and Anne Lesage, Ph.D.
What is Deucrictibant and its significance?
Deucrictibant is an oral bradykinin B2 receptor antagonist being developed for on-demand treatment of hereditary angioedema.
How can I access Pharvaris presentation materials?
The presentations will be available on the Investors section of the Pharvaris website during the respective presentation times.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PHVS Insider Trading Activity
$PHVS insiders have traded $PHVS stock on the open market 34 times in the past 6 months. Of those trades, 0 have been purchases and 34 have been sales.
Here’s a breakdown of recent trading of $PHVS stock by insiders over the last 6 months:
- ANNE LESAGE (Chief Early Development) has made 0 purchases and 10 sales selling 63,000 shares for an estimated $1,901,695.
- JOHANNES GERARDUS CHRISTIAAN PETRUS SCHIKAN has made 0 purchases and 5 sales selling 40,000 shares for an estimated $1,209,926.
- PENG LU (Chief Medical Officer) has made 0 purchases and 6 sales selling 40,000 shares for an estimated $1,206,682.
- BERNDT MODIG (Chief Executive Officer) has made 0 purchases and 4 sales selling 27,917 shares for an estimated $779,816.
- DAVID W. NASSIF (CFO / CLO) sold 10,000 shares for an estimated $303,076
- WIM SOUVERIJNS (Chief Commercial Officer) sold 10,000 shares for an estimated $299,163
- ROBERT GLASSMAN has made 0 purchases and 2 sales selling 10,000 shares for an estimated $298,245.
- ELISABETH BJORK sold 10,000 shares for an estimated $293,166
- VIVIANE MONGES sold 9,667 shares for an estimated $292,853
- STEFAN ANDREAS ABELE (Chief Technical Ops Officer) sold 8,748 shares for an estimated $260,864
- ANNA NIJDAM (Principal Accounting Officer) has made 0 purchases and 2 sales selling 7,330 shares for an estimated $225,055.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PHVS Hedge Fund Activity
We have seen 43 institutional investors add shares of $PHVS stock to their portfolio, and 46 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,835,494 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $50,934,958
- DEERFIELD MANAGEMENT COMPANY, L.P. added 683,578 shares (+28.0%) to their portfolio in Q4 2025, for an estimated $18,969,289
- VR ADVISER, LLC removed 674,599 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $18,720,122
- POLAR CAPITAL HOLDINGS PLC added 543,054 shares (+228.2%) to their portfolio in Q1 2026, for an estimated $15,341,275
- OCTAGON CAPITAL ADVISORS LP removed 506,465 shares (-75.4%) from their portfolio in Q1 2026, for an estimated $14,307,636
- PRICE T ROWE ASSOCIATES INC /MD/ removed 499,349 shares (-53.0%) from their portfolio in Q1 2026, for an estimated $14,106,609
- POINT72 ASSET MANAGEMENT, L.P. added 295,391 shares (+41.5%) to their portfolio in Q1 2026, for an estimated $8,344,795
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$PHVS Analyst Ratings
Wall Street analysts have issued reports on $PHVS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 12/04/2025
- Morgan Stanley issued a "Overweight" rating on 12/04/2025
To track analyst ratings and price targets for $PHVS, check out Quiver Quantitative's $PHVS forecast page.
$PHVS Price Targets
Multiple analysts have issued price targets for $PHVS recently. We have seen 9 analysts offer price targets for $PHVS in the last 6 months, with a median target of $42.0.
Here are some recent targets:
- Jonathan Wolleben from Citizens set a target price of $74.0 on 05/13/2026
- Andy Chen from Wolfe Research set a target price of $42.0 on 04/09/2026
- Laura Chico from Wedbush set a target price of $42.0 on 04/07/2026
- Brian Abrahams from RBC Capital set a target price of $51.0 on 04/06/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $60.0 on 03/03/2026
- Tazeen Ahmad from B of A Securities set a target price of $30.0 on 12/04/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $39.0 on 12/04/2025
Full Release
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of one abstract for oral presentation and seven abstracts for flash talk/poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026 , to be held from June 12-15, 2026, in Istanbul, Turkey.
Details of the presentations are as follows:
-
Title:
Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial
Presenter: Mauro Cancian, M.D., Ph.D.
Format: Oral Presentation
Date, time: Friday, June 12, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)
-
Title:
Clinical Cardiovascular Safety Assessment of Oral Deucrictibant
Presenter: Anne Lesage, Ph.D.
Format: Poster Presentation
Date, time: Friday, June 12, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)
-
Title:
A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema
Presenter: Evangelia Pardali, Ph.D.
Format: Poster Presentation
Date, time: Friday, June 12, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)
-
Title:
Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule
Presenter: Anne Lesage, Ph.D.
Format: Poster Presentation
Date, time: Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)
-
Title:
Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial
Presenter: Philip Li, M.D., FRCP
Format: Poster Presentation
Date, time: Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)
-
Title:
RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
Presenter: Anna Valerieva, M.D., Ph.D.
Format: Poster Presentation
Date, time: Saturday, June 13, 2026, 12:00-1:00 p.m. TRT (5:00-6:00 a.m. EDT)
-
Title:
Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema
Presenter: Markus Magerl, M.D.
Format: Flash Talk
Date, time: Saturday, June 13, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)
-
Title:
CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema
Presenter: Markus Magerl, M.D.
Format: Flash Talk
Date, time: Saturday, June 13, 2026, 3:00-4:30 p.m. TRT (8:00-9:30 a.m. EDT)
The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at:
ir.pharvaris.com/news-events/events-presentations
.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/.
